Biocryst Pharmaceuticals Announces Peramivir Phase 3 Safety & Virology Study Results and Provides a Clinical Program Update

(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced top-line results from one of its two Phase 3 studies of intravenous (i.v.) peramivir for the treatment of patients hospitalized with influenza, and provided an update regarding its peramivir program.

Back to news